Jonathan Gardner
Senior Reporter | @ByJonGardner
885 articles by Jonathan Gardner
-
Boehringer cuts price of Humira biosimilar in bid to build use
July 18, 2024 -
Obesity pill from Roche shows promising weight loss in small study
July 17, 2024 -
Cardurion raises another $260M to fuel heart drug pipeline
July 16, 2024 -
Lilly drug for Alzheimer’s approved by FDA
July 2, 2024 -
Eisai and Bristol Myers cancel cancer ADC deal
July 1, 2024 -
Novo nixes trial of blood pressure drug it bought in $1.3B deal
June 26, 2024 -
Novo to spend $4B on US plant, adding to obesity drug production push
June 25, 2024 -
Obesity drug from Zealand shows potential in early trial
June 20, 2024 -
FDA lifts hold on PTC Huntington’s disease trial
June 20, 2024 -
Takeda drug for rare types of epilepsy misses goal in late-stage trial
June 17, 2024 -
AbbVie joins in latest gastrointestinal drug chase
June 14, 2024 -
Donanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say
June 11, 2024 -
Lilly Alzheimer’s drug gets unanimous backing of FDA panel
June 10, 2024 -
In review of Lilly Alzheimer’s drug, FDA staff focus on safety, patient selection
June 6, 2024 -
Viking says biopsy data confirm MASH drug’s benefit
June 4, 2024 -
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
June 2, 2024 -
GSK builds case for return of multiple myeloma drug Blenrep
June 2, 2024 -
AstraZeneca’s $80B sales plan leans on cancer drug expansion
May 21, 2024 -
AstraZeneca sets sights on $80B in revenue by 2030
May 21, 2024 -
FDA approves Amgen drug for tough-to-treat form of lung cancer
May 17, 2024 -
Roche keeps pace in obesity drug field with early study data
May 16, 2024 -
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
May 13, 2024 -
Drug patents protect pharma profits. Track when they’ll expire.
May 8, 2024 -
AstraZeneca ups stake in Cellectis in latest cell therapy bet
May 6, 2024 -
Amgen shares soar as executives outline obesity drug push
May 3, 2024